Advanced nanoparticle platforms for targeted and controlled RNA delivery.
Core Technology
Platform benefits validated in preclinical models
PoliRNA develops innovative polymer–lipid hybryd nanoparticles for the efficient, safe, and targeted delivery of RNA therapeutics to specific cell populations. The platform is based on a multi-component architecture designed to optimize performance at every stage of delivery.
The PoliRNA nanoparticle consists of a lipid core with high RNA encapsulation efficiency(>95%); a polymeric shell that protects RNA integrity, enhances stability and circulation time, and enables controlled release; a tunable surface functionalization with peptides or antibodies for selective cell targeting.
This integrated design minimizes off-target effects while maximizing therapeutic efficacy and safety.
Our nanoparticles are engineered to protect RNA cargo during
circulation, recognize specific tissue markers, and release their payload
in a controlled manner within target cells.
The platform is designed to be adaptable across different RNA types
including microRNA, siRNA and mRNA, enabling applications in multiple
therapeutic areas.
Therapeutic Effect
Key Advantages
Platform benefits validated in preclinical models
Platform Design
A modular system engineered for versatility and scalability
Therapeutics Applications
Platform versatility enables multiple programs
Validation Approach
From systemic administration to intracellular effect
In Vitro Validation
Platform performance is characterized through cell culture studies evaluating targeting specificity,uptake efficiency, endosomal escape, RNA release kinetics and functional gene modulation across relevant cell types.
In Vivo Studies
Continuos Optimization
